These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 15044616)

  • 1. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity.
    March DR; Proctor LM; Stoermer MJ; Sbaglia R; Abbenante G; Reid RC; Woodruff TM; Wadi K; Paczkowski N; Tyndall JD; Taylor SM; Fairlie DP
    Mol Pharmacol; 2004 Apr; 65(4):868-79. PubMed ID: 15044616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a.
    Wong AK; Finch AM; Pierens GK; Craik DJ; Taylor SM; Fairlie DP
    J Med Chem; 1998 Aug; 41(18):3417-25. PubMed ID: 9719594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a.
    Finch AM; Wong AK; Paczkowski NJ; Wadi SK; Craik DJ; Fairlie DP; Taylor SM
    J Med Chem; 1999 Jun; 42(11):1965-74. PubMed ID: 10354404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity.
    Finch AM; Vogen SM; Sherman SA; Kirnarsky L; Taylor SM; Sanderson SD
    J Med Chem; 1997 Mar; 40(6):877-84. PubMed ID: 9083476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of antagonists of the C5a receptor.
    Paczkowski NJ; Finch AM; Whitmore JB; Short AJ; Wong AK; Monk PN; Cain SA; Fairlie DP; Taylor SM
    Br J Pharmacol; 1999 Dec; 128(7):1461-6. PubMed ID: 10602324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The C terminus of the human C5a receptor (CD88) is required for normal ligand-dependent receptor internalization.
    Bock D; Martin U; Gärtner S; Rheinheimer C; Raffetseder U; Arseniev L; Barker MD; Monk PN; Bautsch W; Köhl J; Klos A
    Eur J Immunol; 1997 Jun; 27(6):1522-9. PubMed ID: 9209506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct binding of a fragment of the Wiskott-Aldrich syndrome protein to the C-terminal end of the anaphylatoxin C5a receptor.
    Tardif M; Brouchon L; Rabiet MJ; Boulay F
    Biochem J; 2003 Jun; 372(Pt 2):453-63. PubMed ID: 12600272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury.
    Heller T; Hennecke M; Baumann U; Gessner JE; zu Vilsendorf AM; Baensch M; Boulay F; Kola A; Klos A; Bautsch W; Köhl J
    J Immunol; 1999 Jul; 163(2):985-94. PubMed ID: 10395696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective hexapeptide agonists and antagonists for human complement C3a receptor.
    Scully CC; Blakeney JS; Singh R; Hoang HN; Abbenante G; Reid RC; Fairlie DP
    J Med Chem; 2010 Jul; 53(13):4938-48. PubMed ID: 20527893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo.
    Pellas TC; Boyar W; van Oostrum J; Wasvary J; Fryer LR; Pastor G; Sills M; Braunwalder A; Yarwood DR; Kramer R; Kimble E; Hadala J; Haston W; Moreira-Ludewig R; Uziel-Fusi S; Peters P; Bill K; Wennogle LP
    J Immunol; 1998 Jun; 160(11):5616-21. PubMed ID: 9605167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of C5a receptor antagonists. Differential loss of functional responses.
    Konteatis ZD; Siciliano SJ; Van Riper G; Molineaux CJ; Pandya S; Fischer P; Rosen H; Mumford RA; Springer MS
    J Immunol; 1994 Nov; 153(9):4200-5. PubMed ID: 7930622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling molecular mechanisms of binding of the anaphylatoxin C5a to the C5a receptor.
    Nikiforovich GV; Marshall GR; Baranski TJ
    Biochemistry; 2008 Mar; 47(10):3117-30. PubMed ID: 18275159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disulfide trapping to localize small-molecule agonists and antagonists for a G protein-coupled receptor.
    Buck E; Wells JA
    Proc Natl Acad Sci U S A; 2005 Feb; 102(8):2719-24. PubMed ID: 15710877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonistic peptides against human anaphylatoxin C5a.
    Kaneko Y; Okada N; Baranyi L; Azuma T; Okada H
    Immunology; 1995 Sep; 86(1):149-54. PubMed ID: 7590876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probing the human receptor for C5a anaphylatoxin with site-directed antibodies. Identification of a potential ligand binding site on the NH2-terminal domain.
    Oppermann M; Raedt U; Hebell T; Schmidt B; Zimmermann B; Götze O
    J Immunol; 1993 Oct; 151(7):3785-94. PubMed ID: 8376805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors.
    Oppermann M; Götze O
    Immunology; 1994 Aug; 82(4):516-21. PubMed ID: 7835913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.
    Wilczynski A; Wang XS; Joseph CG; Xiang Z; Bauzo RM; Scott JW; Sorensen NB; Shaw AM; Millard WJ; Richards NG; Haskell-Luevano C
    J Med Chem; 2004 Apr; 47(9):2194-207. PubMed ID: 15084118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-C5a receptor antibodies. Characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derived from the predicted amino-terminal sequence of the human C5a receptor.
    Morgan EL; Ember JA; Sanderson SD; Scholz W; Buchner R; Ye RD; Hugli TE
    J Immunol; 1993 Jul; 151(1):377-88. PubMed ID: 8326131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solution structure of a unique C5a semi-synthetic antagonist: implications in receptor binding.
    Zhang X; Boyar W; Galakatos N; Gonnella NC
    Protein Sci; 1997 Jan; 6(1):65-72. PubMed ID: 9007977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat.
    Woodruff TM; Strachan AJ; Dryburgh N; Shiels IA; Reid RC; Fairlie DP; Taylor SM
    Arthritis Rheum; 2002 Sep; 46(9):2476-85. PubMed ID: 12355496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.